Schonfeld Strategic Advisors’s C4 Therapeutics CCCC Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$63K	Buy	+23,944	New	+$56.4K	﹤0.01%	1941
2024 Q1	–	Sell	-102,379	Closed	-$578K	–	2095
2023 Q4	$578K	Buy	+102,379	New	+$233K	﹤0.01%	1230
2022 Q4	–	Sell	-23,861	Closed	-$210K	–	2625
2022 Q3	$210K	Buy	+23,861	New	+$248K	﹤0.01%	2304
2022 Q2	–	Sell	-89,662	Closed	-$2.17M	–	2577
2022 Q1	$2.17M	Buy	89,662 +44,550	+99%	+$1.08M	0.02%	703
2021 Q4	$1.45M	Sell	45,112 -17,141	-28%	-$678K	0.01%	792
2021 Q3	$2.78M	Buy	+62,253	New	+$2.67M	0.03%	603

Other funds holding CCCC

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Schonfeld Strategic Advisors's CCCC Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in C4 Therapeutics (CCCC) in Q1 2026: 23,944 shares worth $63K. The stake represents ﹤0.01% of the portfolio and ranks #1941 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in CCCC as recently as Q4 2023.

Schonfeld Strategic Advisors first reported a position in CCCC in Q3 2021 and has held it in 6 quarters since. The position peaked at $2.78M in Q3 2021. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

Schonfeld Strategic Advisors held 23,944 shares of C4 Therapeutics worth $63K as of Q1 2026.
C4 Therapeutics was a new Schonfeld Strategic Advisors position in Q1 2026.
C4 Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1941 holding.
Schonfeld Strategic Advisors first reported a position in C4 Therapeutics in Q3 2021 and has held it in 6 quarters since.
Schonfeld Strategic Advisors's C4 Therapeutics position peaked at $2.78M in Q3 2021.
123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.